Anzeige
Erschienen in:
22.06.2020
Efficacy comparison of laparoscopic sleeve gastrectomy in type 2 diabetes patients with a BMI 30–34.9 kg/m2 versus BMI < 30 kg/m2
Erschienen in: Surgical Endoscopy | Ausgabe 4/2021
Einloggen, um Zugang zu erhaltenAbstract
Background
Laparoscopic sleeve gastrectomy (LSG) is safe and effective in type 2 diabetes mellitus (T2DM) with body mass index (BMI) ≥ 35 kg/m2. However, the effect and safety of LSG in the treatment of T2DM patients with BMI less than 35 kg/m2, especially in patients with BMI less than 30 kg/m2, are still debatable.
Methods
A total of 51 T2DM patients with BMI less than 35 kg/m2 treated successfully with LSG were included in our study. All patients were divided into two groups for subgroup analysis, namely group A (BMI 23.23–29.97 kg/m2) and group B (BMI 30.0–34.9 kg/m2). The weight loss and diabetic characteristics of LSG in the two groups at 3 months, 6 months, and 12 months after operation were compared, respectively.
Results
In group A, the complete remission rates of T2DM were 20%, 36%, and 44% at 3, 6, and 12 months after operation, respectively. In group B, the complete remission rates of T2DM were 30.8%, 61.5%, and 88.5% at 3, 6, and 12 months after operation, respectively. Besides, none of the patients with a duration more than 15 years achieved complete remission. For T2DM patients with BMI < 30 kg/m2 at 12 months after LSG, the complete remission rate of T2DM was 15.4% in patients with ABCD scores ≤ 2, and the complete remission rate of T2DM was 100% in patients with ABCD scores ≥ 5.
Conclusion
LSG is safe and effective for T2DM patients with BMI less than 35 kg/m2 in the short-term. However, the complete remission rate of T2DM in patients with BMI less than 30 kg/m2 is far from the diabetes patients with BMI at 30–34.9 kg/m2.